Rolimus 5mg Tablet

• Treats kidney, breast, pancreatic and lung cancer. Also prevent organ rejection while transplanting body organs.

As with all medicines, Rituximab may affect people differently and some may experience side effects. Most are temporary or mild, consult the healthcare professional if any of the symptoms persist or worsen:

• Infection (chills, increased temperature)
• Coughing
• Wheezing
• Excessive thirst
• High urine output or severely decreased urine output
• Tiredness
• Bleeding
• Increased appetite with weight loss
• Difficulty breathing, or swallowing
• Swelling of face, lips, tongue, throat
• Severe itching, red rash, raised bumps​

• The dosage and number of infusions depend on the type of cancer or autoimmune condition being treated. The injection is usually given in hospital or clinics by a nurse or healthcare professional through intravenous infusion.
• Treatment schedule can range from single infusion to multiple infusion over several weeks. Do not self administered, consult the doctor about correct dosage and duration before using Rolimus 5mg tablet.
  
  

• Rolimus 5mg tablet inhibits the mTOR pathway, which plays a key role in cell growth, division and blood formation. By blocking this pathway, it helps to control the growth of cancerous cells and reduces harmful immune activity in autoimmune conditions.
• It also suppresses immune cell activity, helping to prevent organ rejection after transplantation, thereby improving treatment effectiveness and long term patient outcomes.
  
  

• Houghton, P. J. (2010). Everolimus. Clinical cancer research, 16(5), 1368-1372. https://pubmed.ncbi.nlm.nih.gov/20179227/
• Hasskarl, J. (2018). Everolimus. Small molecules in oncology, 101-123. https://link.springer.com/book/10.1007/978-3-319-91442-8
• Kirchner, G. I., Meier-Wiedenbach, I., & Manns, M. P. (2004). Clinical pharmacokinetics of everolimus. Clinical pharmacokinetics, 43(2), 83-95. https://pubmed.ncbi.nlm.nih.gov/14748618/
• Chapman, T. M., & Perry, C. M. (2004). Everolimus. Drugs, 64(8), 861-872. https://pubmed.ncbi.nlm.nih.gov/15059040/
• Atkins, M. B., Yasothan, U., & Kirkpatrick, P. (2009). Everolimus. Nature reviews Drug discovery, 8(7), 535-536. https://pubmed.ncbi.nlm.nih.gov/19568281/​